Neurocrine Biosciences, Inc. (NBIX)

NASDAQ: NBIX · Real-Time Price · USD

163.12

-0.76 (-0.46%)

At close: Jun 8, 2026, 4:00 PM EDT

164.77

+1.65 (1.01%)

After-hours: Jun 8, 2026, 5:49 PM EDT

Neurocrine Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	668.6	478.6	341.3	249.7	154.5	89.6
Depreciation & Amortization	29.8	30.1	27.1	21.3	15.6	10.9
Stock-Based Compensation	222.3	217.9	195.5	194.3	173.1	134.2
Other Adjustments	43.55	184.9	50.7	-103.6	63.6	5.1
Change in Receivables	-255	-210.5	-39.8	-89.3	-162.2	-28.4
Changes in Inventories	-9.3	-15.3	-19.1	5.4	-2.6	-2.5
Changes in Accounts Payable	133.5	160.2	43.4	49	114.6	56.8
Changes in Income Taxes Payable	155.3	-18.8	50.3	91.6	-	-
Changes in Other Operating Activities	-78.3	-44.4	-54	-28.5	-17.2	-9.2
Operating Cash Flow	863.7	782.7	595.4	389.9	339.4	256.5
Operating Cash Flow Growth	62.99%	31.46%	52.71%	14.88%	32.32%	12.25%
Capital Expenditures	-32.4	-34	-38.2	-28.3	-16.5	-23.4
Purchases of Investments	-1,866	-1,320	-1,056	-1,411	-628.9	-804.7
Proceeds from Sale of Investments	1,051	1,089	967.5	972.4	511	697.9
Payments for Business Acquisitions	-	-	-	-	-42.7	-
Proceeds from Business Divestments	63.2	-	-	-	-	-
Investing Cash Flow	-784.8	-264.4	-126.8	-467.1	-177.1	-130.2
Long-Term Debt Repaid	-	-	-308.8	-	-279	-0.1
Net Long-Term Debt Issued (Repaid)	-	-	-308.8	-	-279	-0.1
Issuance of Common Stock	120.9	129.4	122.1	65.3	44.7	27.5
Repurchase of Common Stock	-71.7	-167.7	-300	-	-	-
Net Common Stock Issued (Repurchased)	49.2	-38.3	-177.9	65.3	44.7	27.5
Other Financing Activities	-55.7	-	-	-	-	-
Financing Cash Flow	-6.5	-38.3	-486.7	65.3	-234.3	27.4
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0.1	-	-	0.3	-1.3	-
Net Cash Flow	72.4	480	-18.1	-11.6	-73.3	153.7
Free Cash Flow	831.3	748.7	557.2	361.6	322.9	233.1
Free Cash Flow Growth	11.03%	34.37%	54.09%	11.98%	38.52%	7.12%
FCF Margin	26.80%	26.17%	23.66%	19.16%	21.69%	20.56%
Free Cash Flow Per Share	8.10	7.30	5.37	3.58	3.26	2.38
Levered Free Cash Flow	867.2	556.4	42	360.2	-30.6	122.1
Unlevered Free Cash Flow	761.22	497.85	410.14	299.15	273.75	123.17

SEC Filings: 10-K · 10-Q